SCHEMBL21027604

SCHEMBL21027604

CCN1c2nc(Cc3cn4ccsc4n3)n(Cc3ccccc3)c2C(=O)NC1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TPH1 P17752 14/20 0.58
▸ TPH2 Q8IWU9 11/20 0.58
▸ TSHR P16473 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NPC1 O15118 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19827284 0.87 TPH1 (0.55) TPH1TPH2TSHRALDH1A1HPGD
SCHEMBL19827204 0.83 TPH1 (0.59) TPH1TPH2TSHRALDH1A1HPGD
SCHEMBL21027845 0.77 TPH1 (0.57) TPH1TPH2
SCHEMBL19810115 0.73 TPH1 (1.00) TPH1TPH2
SCHEMBL21027610 0.72 TPH2 (0.63) TPH1TPH2SMN1; SMN2
SCHEMBL22105455 0.69 KMT2A (0.33) TSHRALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL22105567 0.66 TSHR (0.45) TSHRALDH1A1SMN1; SMN2TDP1GAA
SCHEMBL21027606 0.66 TPH1 (0.63) TPH1TPH2
SCHEMBL21316270 0.63 F11 (0.37) ALDH1A1NPC1TDP1MAPT
SCHEMBL5958170 0.61 TRPA1 (0.73) TPH1TPH2TSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683309-B2 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same Max-Delbrück-Centrum für Molekulare Medizin (DE) 2020-06-16 — — US disclosed
US-20190161503-A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME Max-Delbrück-Centrum für Molekulare Medizin (DE) 2019-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683309-B2 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same TPH1, XDH, TPH2 TPH1 1/4885TPH2 3/4885TSHR 1442/4885
US-20190161503-A1 XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME TPH1, XDH, TPH2 TPH1 1/4885TPH2 3/4885TSHR 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback